Orgenesis (ORGS) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research lowered shares of Orgenesis (OTCMKTS:ORGS) from a hold rating to a sell rating in a report published on Saturday, Zacks.com reports.

According to Zacks, “Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing Organization and Cellular Therapy Business. Contract Development and Manufacturing Organization segment activity includes MaSTherCell, which specializes in cell therapy development for advanced medicinal products. Cellular Therapy Business segment activity is based on its technology which demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell like insulin producing cells for patients with Type 1 Diabetes. Orgenesis, Inc. is headquartered in Germantown, MD. “

Shares of OTCMKTS ORGS opened at $4.50 on Friday. Orgenesis has a 52-week low of $3.87 and a 52-week high of $9.50.

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Orgenesis by 63.2% in the 3rd quarter. Vanguard Group Inc. now owns 236,324 shares of the company’s stock worth $1,309,000 after buying an additional 91,507 shares during the last quarter. Vanguard Group Inc increased its holdings in shares of Orgenesis by 63.2% in the 3rd quarter. Vanguard Group Inc now owns 236,324 shares of the company’s stock worth $1,309,000 after buying an additional 91,507 shares during the last quarter. Geode Capital Management LLC bought a new stake in shares of Orgenesis in the 4th quarter worth about $212,000. Cheyne Capital Management UK LLP bought a new stake in shares of Orgenesis in the 4th quarter worth about $183,000. Finally, BlackRock Inc. increased its holdings in shares of Orgenesis by 44.6% in the 4th quarter. BlackRock Inc. now owns 28,886 shares of the company’s stock worth $135,000 after buying an additional 8,909 shares during the last quarter.

About Orgenesis

Orgenesis Inc is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company’s subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products.

Featured Story: What is a short straddle?

Get a free copy of the Zacks research report on Orgenesis (ORGS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.